drugset

drugset / Trial / NCT03535753

Safety and Efficacy Evaluation of Decitabine With R-GDP

NCT03535753 ↗

Phase 1 Unknown 50 enrolled Beijing Immunochina Medical Science & Technology Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

Assessment of the Safety and efficacy of Administering decitabin plus R-GDP to NHL patients

Timeline

Start: 2017-09-01
Primary completion: 2020-09-01
Completion: 2020-11-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Decitabine	Small molecule	—	—

Indications